Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

281. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials

An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials Borgstrom F, Jonsson B, Strom O, Kanis J (...) to the "classical" hip, vertebral and wrist fracture types, the authors incorporated an additional health state representing other osteoporotic fracture types, thus making the model more comprehensive. The cycle length in the model was 1 year. The patients were followed through the model from the age of treatment initiation. Sources searched to identify primary studies The effective evidence was derived from two large multi-centre randomised controlled trials (RCTs), namely, the Spinal Osteoporosis Therapeutic

2006 NHS Economic Evaluation Database.

282. Cost-effectiveness analysis of various screening methods for osteoporosis in perimenopausal Thai women

Cost-effectiveness analysis of various screening methods for osteoporosis in perimenopausal Thai women Cost-effectiveness analysis of various screening methods for osteoporosis in perimenopausal Thai women Cost-effectiveness analysis of various screening methods for osteoporosis in perimenopausal Thai women Panichkul S, Panichkul P, Sritara C, Tamdee D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of screening strategies for the detection of osteoporosis in perimenopausal women. These strategies were compared with no intervention and with universal treatment. The analysis demonstrated that no intervention was the most cost-effective strategy, while screening with risk index

2006 NHS Economic Evaluation Database.

283. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada Full Text available with Trip Pro

Cost-effectiveness of alternative treatments for women with osteoporosis in Canada Cost-effectiveness of alternative treatments for women with osteoporosis in Canada Cost-effectiveness of alternative treatments for women with osteoporosis in Canada Goeree R, Blackhouse G, Adachi J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four pharmacological therapies for women with osteoporosis were examined. These were three bisphosphonates (etidronate, alendronate and risedronate) and raloxifene. Raloxifene was assumed to be given at a dose of 60 mg/day, alendronate at 70 mg once weekly, and risedronate at 35 mg once weekly. Patients on etidronate were assumed to be taking a regimen pack of 400 mg for 14 days, followed by 500 mg

2006 NHS Economic Evaluation Database.

284. Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women

Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women Lundkvist J, Johnell O, Cooper C, Sykes D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) density (BMD) T-score of less than or equal to -3.0. Also, the study indicated that the cost-effectiveness of treatments for osteoporosis is highly dependent on the timing of treatment initiation relative to the fracture. CRD COMMENTARY - Selection of comparators The comparator was calcium and vitamin D alone. The authors acknowledged the existence of other treatments for osteoporosis but said that there were no clinical trials comparing them with teriparatide that had fracture as a primary end point

2006 NHS Economic Evaluation Database.

285. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis Full Text available with Trip Pro

The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis Liu H, Michaud K, Nayak S, Karpf D B, Owens D K, Garber A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined three treatment strategies for postmenopausal women with severe osteoporosis: usual care (UC) based on calcium or vitamin D plus 5 years of alendronate therapy (alendronate alone); UC plus 2 years of teriparatide therapy (teriparatide alone); and UC plus 2 years of teriparatide therapy followed

2006 NHS Economic Evaluation Database.

286. Strontium ranelate reduced the risk of vertebral fractures in postmenopausal women with osteoporosis Full Text available with Trip Pro

Strontium ranelate reduced the risk of vertebral fractures in postmenopausal women with osteoporosis Strontium ranelate reduced the risk of vertebral fractures in postmenopausal women with osteoporosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Strontium ranelate reduced the risk of vertebral fractures in postmenopausal women with osteoporosis Article Text Therapeutics Strontium ranelate reduced the risk of vertebral fractures

2005 Evidence-Based Medicine

287. Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study. Full Text available with Trip Pro

Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study. To determine whether measuring monoclonal bands (M component) in serum should be part of the investigation of patients referred to osteoporosis clinics.Retrospective, cross sectional, observational study.Referral centre for osteoporosis in a university hospital, Denmark.799 people (685 women) aged 19 to 94 years newly referred with suspected osteoporosis.Proportion (...) of patients fulfilling the Nordic Myeloma Study Group definition for target condition and proportion of patients with other important haematological conditions.4.9% (18 of 366) of patients with osteoporosis and 2.2% (9 of 408) of patients without osteoporosis had M component in serum (chi2 = 3.66, P = 0.04). Multiple myeloma was diagnosed in three patients with osteoporosis (absolute risk 0.8%, 95% confidence interval 0.11% to 1.7%). The relative risk of multiple myeloma in patients presenting

2005 BMJ

288. Association between screening for osteoporosis and the incidence of hip fracture. (Abstract)

Association between screening for osteoporosis and the incidence of hip fracture. Because direct evidence for the effectiveness of screening is lacking, guidelines disagree on whether people should be screened for osteoporosis.To determine whether population-based screening for osteoporosis in older adults is associated with fewer incident hip fractures than usual medical care.Nonconcurrent cohort study.Population-based cohort enrolled in the Cardiovascular Health Study (CHS) from 4 states (...) the observed association.Use of hip DEXA scans to screen for osteoporosis in older adults was associated with 36% fewer incident hip fractures over 6 years compared with usual medical care. Further research is needed to explore the mechanism of this association.

2005 Annals of Internal Medicine

289. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. Full Text available with Trip Pro

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. Since the use of parathyroid hormone as a treatment for osteoporosis is limited to two years or less, the question of whether antiresorptive therapy should follow parathyroid hormone therapy is important. We previously reported results after the first year of this randomized trial comparing the use of full-length parathyroid hormone (1-84) alone, alendronate alone, or both combined. In the continuation

2005 NEJM Controlled trial quality: uncertain

290. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment (...) of postmenopausal osteoporosis Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention

2005 Health Technology Assessment (HTA) Database.

291. Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis or malignancy

Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis or malignancy Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis or malignancy Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis or malignancy BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield (...) Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis or malignancy. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 20(7). 2005 Authors' objectives This Assessment evaluates the available evidence to determine whether kyphoplasty (KP

2005 Health Technology Assessment (HTA) Database.

292. Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis or malignancy

Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis or malignancy Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis or malignancy Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis or malignancy BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield (...) Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis or malignancy. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 20(6). 2005 Authors' objectives This Assessment evaluates the available evidence to determine whether percutaneous

2005 Health Technology Assessment (HTA) Database.

293. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis

Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

294. Clinical risk indices, prediction of osteoporosis, and prevention of fractures: diagnostic consequences and costs

Clinical risk indices, prediction of osteoporosis, and prevention of fractures: diagnostic consequences and costs Clinical risk indices, prediction of osteoporosis, and prevention of fractures: diagnostic consequences and costs Clinical risk indices, prediction of osteoporosis, and prevention of fractures: diagnostic consequences and costs Pongchaiyakul C, Nguyen ND, Eisman JA, Nguyen TV Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared bone mineral density measurement against the Osteoporosis Self-Assessment Tool for Asians (OSTA) for diagnosing osteoporosis in women and preventing fractures. When the OSTA was applied in low-risk populations, it had a low positive predictive value, resulted in many false

2005 NHS Economic Evaluation Database.

295. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women

Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women Schousboe J T, Ensrud K E, Nyman J (...) with osteoporosis (femoral neck T-score >/= -2.5). Type of intervention Screening and treatment. Economic study type Cost-utility analysis. Study population The study population comprised women aged 65 years and older. Both women living independently and those residing in nursing homes were considered. Setting The setting was primary care. The economic study was carried out in the USA. Dates to which data relate The effectiveness data and some resource use data were derived from studies published between 1982

2005 NHS Economic Evaluation Database.

296. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. Full Text available with Trip Pro

Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. Both bone mineral density (BMD) and fracture risk have a strong genetic component. Estrogen receptor alpha (ESR1) is a candidate gene for osteoporosis, but previous studies of ESR1 polymorphisms in this field were hampered by small sample size, lack of standardization, and inconclusive results.To generate large-scale evidence on whether 3 common ESR1 polymorphisms (intron 1 polymorphisms XbaI [dbSNP: rs9340799

2004 JAMA

297. Preliminary clinical criteria had moderate sensitivity but low specificity for detecting osteoporosis in rheumatoid arthritis Full Text available with Trip Pro

Preliminary clinical criteria had moderate sensitivity but low specificity for detecting osteoporosis in rheumatoid arthritis Preliminary clinical criteria had moderate sensitivity but low specificity for detecting osteoporosis in rheumatoid arthritis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Preliminary clinical criteria had moderate sensitivity but low specificity for detecting osteoporosis in rheumatoid arthritis Article Text

2004 Evidence-Based Medicine

298. Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis and malignancy, or hemangioma

Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis and malignancy, or hemangioma Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis and malignancy, or hemangioma Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis and malignancy, or hemangioma BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis and malignancy, or hemangioma. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 19(13). 2004 Authors' objectives This Assessment evaluates

2004 Health Technology Assessment (HTA) Database.

299. Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis and malignancy

Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis and malignancy Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis and malignancy Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis and malignancy BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield (...) Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Percutaneous kyphoplasty for vertebral fractures caused by osteoporosis and malignancy. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 19(12). 2004 Authors' objectives This Assessment evaluates the available evidence to determine whether kyphoplasty is demonstrated

2004 Health Technology Assessment (HTA) Database.

300. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis

Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis Effects of omega-3 fatty acids on lipids (...) and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis MacLean CH, Mojica WA, Morton SC, Pencharz J, Hasenfeld Garland R, Tu W, Newberry SJ, Jungvig LK, Grossman J, Khanna P, Rhodes S, Shekelle P Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made

2004 Health Technology Assessment (HTA) Database.